Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

They are generated from arachidonate by the action of cyclooxygenase isoenzymes, and their biosynthesis is blocked by nonsteroidal antiinflammatory drugs, including those selective for inhibition of ...

This five-year analysis of the C-144-01 trial represents unprecedented durability and duration of follow-up in advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where ...

The empirical dietary inflammatory pattern (EDIP) score, used in the study to measure the inflammatory potential of patients' ...

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

“The FDA’s decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people ...

Curcumin, a phenolic antioxidant extracted from the rhizomes of turmeric and other Curcuma species, possesses strong ...

Recent research points to the potential utility of a familiar sounding foe–herpes virus–in the fight against cancer.

Low-dose interleukin-2 (IL-2 LD) can expand and activate Tregs and has, therefore, a therapeutic potential in SSc. Objective We aimed to assess the safety and biological efficacy of IL-2 LD in ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...